Skip to main content
ADHERIUM LIMITED logo

ADHERIUM LIMITED — Investor Relations & Filings

Ticker · ADR ISIN · AU000000ADR1 ASX Manufacturing
Open in API
Filings indexed 872 across all filing types
Latest filing 2026-05-28 Investor Presentation
Country AU Australia
Listing ASX ADR

About ADHERIUM LIMITED

https://www.adherium.com

Adherium Limited is a digital health company specializing in the development and commercialization of connected medical devices and software solutions for chronic respiratory management. The company's primary offering is the Hailie® platform, which consists of advanced sensors that attach to various inhaler medications to monitor usage and technique. These sensors transmit data via Bluetooth to a mobile application and a cloud-based portal, providing patients and healthcare providers with real-time insights into medication adherence and respiratory health trends. By facilitating remote patient monitoring and data-driven clinical decisions, Adherium aims to improve health outcomes for individuals living with asthma and chronic obstructive pulmonary disease (COPD). The platform is utilized by healthcare systems, pharmaceutical companies, and clinical research organizations to enhance patient engagement and optimize treatment efficacy.

Recent filings

Filing Released Lang Actions
Adherium Investor Webinar 2 pages 172.5KB
Investor Presentation Classification · 80% confidence The document is an ASX release announcing and inviting investors to register for a virtual investor webinar led by the CEO and SVP, focusing on strategy, commercial pathway, and near-term milestones. It is not a financial results announcement (ER), not a regulatory filing of a published report (RPA), and contains no transcript or financial statements. This is an investor presentation notice, fitting the Investor Presentation (IP) category.
2026-05-28 English
Notice of Extraordinary General Meeting/Proxy Form 74 pages 1.8MB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is the formal Notice of Extraordinary General Meeting (EGM) of Adherium Limited, including the agenda, resolutions, explanatory memorandum, and proxy voting instructions. It is a solicitation of proxies and information for a shareholder meeting, which corresponds to the definition of a Proxy Solicitation & Information Statement.
2026-05-20 English
Notice of Share Consolidation 2 pages 115.7KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX release titled “Notice of Share Consolidation” detailing a proposed consolidation of every 100 ordinary shares into one share, including the timetable under ASX Listing Rule 7.22. This is a capital structure change (stock consolidation), fitting the “Share Issue/Capital Change” category.
2026-05-20 English
Consolidation/Split - ADR 5 pages 20.2KB
Share Issue/Capital Change Classification · 95% confidence The document is a formal ASX Appendix 3A.3 announcement detailing a security consolidation (reverse share split), including record dates, meeting approvals, pre- and post-consolidation share counts, exercise prices, and timetable. This is a corporate capital change notification rather than a full financial report or regulatory notice of publication. It falls under Share Issue/Capital Change.
2026-05-20 English
ATS 2026 Evidence Supports Adherium Growth Strategy 6 pages 293.5KB
Regulatory Filings Classification · 60% confidence The document is an ASX Release press announcement regarding clinical study data presentations at ATS 2026. It is not a full financial report, earnings release, management/call transcript, or other specific filing type. It primarily serves as a regulatory announcement of corporate news on the ASX. It does not include financial statements or request shareholder actions, nor is it a publication of an official report. Under the taxonomy, this best fits as a general regulatory announcement (Regulatory Filings).
2026-05-17 English
Quarterly Activities/Appendix 4C Cash Flow Report 15 pages 583.8KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX Release titled 'Appendix 4C Quarterly Cash Flow Report to 31 March 2026' and provides detailed quarterly financial and operational metrics, including cash flow, revenue growth, device shipments, patient activations, and commercial milestones for the quarter ended 31 March 2026. It contains substantive financial data and analysis for a quarter, not just an announcement or summary. The presence of detailed quarterly financial performance and operational updates aligns with the definition of an Interim / Quarterly Report (IR). The document is about 15,000 characters, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2026
2026-04-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.